CLINICAL PHARMACOKINETICS OF ADAVOSERTIB IN THE PRESENCE OR ABSENCE OF PD-L1 INHIBITOR DURVALUMAB IN PATIENTS WITH REFRACTORY SOLID TUMORS.

Miah K.; Imedio E.; Kumar S.; Ottesen L.; Mugundu G.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >CLINICAL PHARMACOKINETICS OF ADAVOSERTIB IN THE PRESENCE OR ABSENCE OF PD-L1 INHIBITOR DURVALUMAB IN PATIENTS WITH REFRACTORY SOLID TUMORS.

【24h】

CLINICAL PHARMACOKINETICS OF ADAVOSERTIB IN THE PRESENCE OR ABSENCE OF PD-L1 INHIBITOR DURVALUMAB IN PATIENTS WITH REFRACTORY SOLID TUMORS.

机译：在难治性固体瘤患者中，Adavosertib的临床药代动力学在PD-L1抑制剂Durvalumab中的存在或不存在。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2020年第s1期|共1页
作者
Miah K.; Imedio E.; Kumar S.; Ottesen L.; Mugundu G.;
展开▼
作者单位

AstraZeneca Boston MA USA;

AstraZeneca Cambridge England;

AstraZeneca Cambridge England;

AstraZeneca Cambridge England;

AstraZeneca Boston MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. CLINICAL PHARMACOKINETICS OF ADAVOSERTIB IN THE PRESENCE OR ABSENCE OF PD-L1 INHIBITOR DURVALUMAB IN PATIENTS WITH REFRACTORY SOLID TUMORS. [J] . Miah K., Imedio E., Kumar S., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：在难治性固体瘤患者中，Adavosertib的临床药代动力学在PD-L1抑制剂Durvalumab中的存在或不存在。
2. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. [J] . Mahadevan D, Plummer R, Squires MS, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第9期

机译：AT7519（细胞周期蛋白依赖性激酶抑制剂）在难治性实体瘤患者中的I期药代动力学和药效学研究。
3. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. [J] . Minami H, Kawada K, Ebi H, Cancer science. . 2008,第7期

机译：口服多激酶抑制剂索拉非尼在日本患有晚期难治性实体瘤的患者的第一阶段和药代动力学研究。
4. Development of a HPLC-MS/MS assay to measure the novel angiogenesis inhibitor E-3810 in plasma. Preliminary pharmacokinetic evaluation in cancer patients [C] . Federica Sala, Valeria Livi, Roberta Cereda, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：培养HPLC-MS / MS测定以测量血浆中的新型血管生成抑制剂E-3810。癌症患者的初步药代动力学评估
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
6. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors [O] . Mats Någård, Mei-Lin Ah-See, Karen So, -1

机译：食物对晚期实体瘤患者WEE1抑制剂adavosertib（AZD1775）药代动力学的影响
7. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. [O] . Leijen, S, Soetekouw, PM, Jeffry Evans, TR, 2011

机译：I期开放标签，随机交叉研究，用于评估在患有或不患有食物的晚期实体瘤患者中，MEK 1/2抑制剂Selumetinib（AZD6244; ARRY-142866）的剂量给药效果。

CLINICAL PHARMACOKINETICS OF ADAVOSERTIB IN THE PRESENCE OR ABSENCE OF PD-L1 INHIBITOR DURVALUMAB IN PATIENTS WITH REFRACTORY SOLID TUMORS.

著录项

相似文献

相关主题

期刊订阅